Kolexia
Lerebours Florence Oncologie médicale
Lerebours Florence
Oncologie médicale
Institut Curie
Saint-Cloud, France
195 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Cancers du sein inflammatoires Métastase tumorale Fatigue Cellules tumorales circulantes Tumeurs du sein triple-négatives Carcinomes Carcinome canalaire du sein Récidive tumorale locale

Collaborateurs

Voir plus
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France
Cottu Paul-Henri
Cottu Paul-Henri
Clcc Institut Curie, Paris, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Lilly
13 collaboration(s)
Dernière en 2023
Roche
12 collaboration(s)
Dernière en 2022
Gilead
8 collaboration(s)
Dernière en 2023
Eisai
7 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
TUC-TOC: Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II
Essai Clinique (Seagen)   07 mars 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Oncogene   27 février 2024
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Essai Clinique (Novartis)   26 février 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
GrannyFit: Digital Phenotyping (Physical Activity, Sleep) in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment
Essai Clinique (Institut Curie)   26 janvier 2024
NeoFit: Digital Phenotyping (Physical Activity, Heart Rate, Sleep) in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
Essai Clinique (Institut Curie)   26 janvier 2024
Treatment response, tumor infiltrating lymphocytes and clinical outcomes in inflammatory breast cancer treated with neoadjuvant systemic therapy.
Cancer research communications   26 décembre 2023
Tolerance of concurrent adjuvant radiotherapy and pembrolizumab for triple negative breast cancer: real life experience
Advances in radiation oncology   17 octobre 2023
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Journal of the National Cancer Institute   08 septembre 2023